| Lung Non-Small Cell Carcinoma26 |
|---|
| EGFR Exon 19 Deletion | Afatinib | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID2996Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who h… (full text at CIViC) PMID 23982599 · Dungo et al., 2013 · Open in CIViC | civic |
| EGFR Exon 19 Deletion | Afatinib | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID881Stable HEK293 cell lines expressing mutant EGFR cDNAs were created (using a pQCLIN retroviral vector) and their drug sensitivities to afatinib were examined by MTT assay. Phorphorylation of EGFR was a… (full text at CIViC) PMID 25862853 · Banno et al., 2015 · Open in CIViC | civic |
| EGFR Exon 19 Deletion | Afatinib | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID969Cells harboring an exon 19 deletion were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to dir… (full text at CIViC) PMID 26515464 · Hirano et al., 2015 · Open in CIViC | civic |
| EGFR Exon 19 Deletion | Anti-PD1 Monoclonal Antibody | Predictive | B | Supports Resistance | 4 | accepted | EID7586In a multicenter retrospective study, the relationship between EGFR status in 171 patients with non-small cell lung carcinoma and response to immune checkpoint blockade was examined.
Immune checkpoint… (full text at CIViC) PMID 31086949 · Hastings et al., 2019 · Open in CIViC | civic |
| EGFR Exon 19 Deletion | Anti-PD-L1 Monoclonal Antibody | Predictive | B | Supports Resistance | 4 | accepted | EID7587In a multicenter retrospective study, the relationship between EGFR status in 171 patients with non-small cell lung carcinoma and response to immune checkpoint blockade was examined.
Immune checkpoint… (full text at CIViC) PMID 31086949 · Hastings et al., 2019 · Open in CIViC | civic |
| EGFR Exon 19 Deletion | Dacomitinib + ErlotinibSubstitutes | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID4859Non-small cell cancer patients from two studies [The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)] with exon 19 deletion and L858R EGFR (Exon 21) mutations were pooled to compare the efficacy … (full text at CIViC) PMID 26768165 · Ramalingam et al., 2016 · Open in CIViC | civic |
| EGFR Exon 19 Deletion | Deguelin | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID12205Deguelin exhibits a potent inhibitory effect in gefitinib-sensitive HCC827 cells with exon 19 deletion (EGFR E746-A750). Both deguelin and gefitinib significantly suppressed EGFR kinase activity, redu… (full text at CIViC) PMID 32081857 · Gao et al., 2020 · Open in CIViC | civic |
| EGFR Exon 19 Deletion | Erlotinib | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID2995On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epider… (full text at CIViC) PMID 24868098 · Khozin et al., 2014 · Open in CIViC | civic |
| EGFR Exon 19 Deletion | Erlotinib | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID884A randomized phase 3 trial involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were random… (full text at CIViC) PMID 22285168 · Rosell et al., 2012 · Open in CIViC | civic |
| EGFR Exon 19 Deletion | Gefitinib | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID166690 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were treated with gefitinib, and exon 19 deletion of EGFR was associated with longer time to treatment failure than those with wild-t… (full text at CIViC) PMID 18509184 · Yang et al., 2008 · Open in CIViC | civic |
| EGFR Exon 19 Deletion | Gefitinib | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID273Exon 19 deletion has been shown to be correlated with gefitinib response. PMID 16730237 · Ji et al., 2006 · Open in CIViC | civic |
| EGFR Exon 19 Deletion | Erlotinib + GefitinibSubstitutes | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID413NSCLC patients with exon 19 deletions in EGFR had longer overall survival than patients with an L858R mutation when treated with gefitinib or erlotinib (38 versus 17 months; P = 0.04). PMID 16818686 · Jackman et al., 2006 · Open in CIViC | civic |
| EGFR Exon 19 Deletion | Afatinib + Erlotinib + GefitinibSubstitutes | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID12202The goal of this study was to assess the frequency, overall survival, and classifying actionability of EGFR mutations in NSCLC within the Dutch population from 2013-2017. This study found that despite… (full text at CIViC) PMID 34298851 · Koopman et al., 2021 · Open in CIViC | civic |
| EGFR L858R OR EGFR Exon 19 Deletion | Amivantamab + Carboplatin + PemetrexedCombination | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID12156In this phase III trial, 657 patients with locally advanced or metastatic NSCLC (Non-Small Cell Lung Cancer) harbouring EGFR mutations (exon 19 deletions or L858R) were treated with amivantamab plus c… (full text at CIViC) PMID 37879444 · Passaro et al., 2024 · Open in CIViC | civic |
| EGFR L858R OR EGFR Exon 19 Deletion | Amivantamab + LazertinibCombination | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID12131In this trial (MARIPOSA), 1074 patients with Non-Small Cell Lung Cancer harbouring exon 19 deletion or exon 21 L858R substitution were randomized (2:2:1) to receive lazertinib-amivantamab (n=429), osi… (full text at CIViC) PMID 38942080 · Felip et al., 2024 · Open in CIViC | civic |
| EGFR L858R OR EGFR Exon 19 Deletion | Carboplatin OR Cisplatin + Pembrolizumab + PemetrexedCombination | Predictive | B | Supports Resistance | 5 | submitted | EID13097In the randomized, double-blind phase III KEYNOTE-789 trial, 492 patients with EGFR exon 19 deletion- or L858R-positive, TKI-resistant metastatic nonsquamous non-small-cell lung cancer received pemetr… (full text at CIViC) PMID 39173098 · Yang et al., 2024 · Open in CIViC | civic |
| EGFR L858R OR EGFR Exon 19 Deletion | Dacomitinib | Predictive | A | Supports Sensitivity Response | 4 | rejected | EID7363In this phase 3, open-label, randomized trial, 452 patients with EGFR mutation-positive non-small cell lung cancer including exon 19 deletions and exon 21 L858R point mutations were randomized into co… (full text at CIViC) PMID 28958502 · Wu et al., 2017 · Open in CIViC | civic |
| EGFR L858R OR EGFR Exon 19 Deletion | Dacomitinib | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID11239In this phase 3, open-label, randomized trial, 452 patients with EGFR mutation-positive non-small cell lung cancer including exon 19 deletions and exon 21 L858R point mutations were randomized into co… (full text at CIViC) PMID 28958502 · Wu et al., 2017 · Open in CIViC | civic |
| EGFR L858R OR EGFR Exon 19 Deletion | Erlotinib + GefitinibSubstitutes | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID4759In a study of 1261 non-small cell lung cancer patients, 49.8% of the analyzed tumors had EGFR mutations including deletions in exon 19 (n=258), L858R (n=260), T790M (n=6) and insertions or duplication… (full text at CIViC) PMID 21531810 · Wu et al., 2011 · Open in CIViC | civic |
| EGFR L858R OR EGFR Exon 19 Deletion | Erlotinib + RamucirumabCombination | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID11240In this phase 3, randomized, double-blind, placebo-controlled trial, 449 patients stage IV NSCLC with EGFR exon 19 deletions or exon 21 (L858R) mutations. Patients were randomly assigned in a 1:1 rati… (full text at CIViC) PMID 31591063 · Nakagawa et al., 2019 · Open in CIViC | civic |
| EGFR L858R OR EGFR Exon 19 Deletion | Gefitinib | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID11241In this phase-IV, open-label, single-arm study, 106 patients with NSCLC and EGFR mutations including exon 19 deletion and exon 21 L858R point mutations were administered 250 mg daily doses of gefitini… (full text at CIViC) PMID 24263064 · Douillard et al., 2014 · Open in CIViC | civic |
| EGFR L858R OR EGFR Exon 19 Deletion | Gefitinib | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID2156A phase 2 study of 120 stage IIIB-IV lung adenocarcinoma patients reported improved progression free survival in patients with EGFR mutation (defined as exon 19 deletion or exon 21 mutation) when trea… (full text at CIViC) PMID 24755888 · Yu et al., 2014 · Open in CIViC | civic |
| EGFR L858R OR EGFR Exon 19 Deletion | Osimertinib | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID11219In this phase 3, double-blind trial, 682 patients were randomly assigned 1:1 to either osimertinib (80 mg once daily) or placebo for 3 years following complete resection of EGFR mutation positive (exo… (full text at CIViC) PMID 32955177 · Wu et al., 2020 · Open in CIViC | civic |
| EGFR L858R OR EGFR Exon 19 Deletion | Osimertinib | Predictive | A | Supports Sensitivity Response | 5 | submitted | EID12144The phase 3 randomized LAURA trial (NCT NCT03521154) evaluated osimertinib as consolidation therapy after definitive chemoradiation in 216 patients with unresectable stage 3 non-small cell lung cancer… (full text at CIViC) PMID 38828946 · Lu et al., 2024 · Open in CIViC | civic |
| EGFR L858R OR EGFR Exon 19 Deletion | Chemotherapy + OsimertinibCombination | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID12015In this phase 3 clinical trial, 557 patients with NSCLC harbouring EGFR mutations (exon 19 deletion or L858R mutation) were randomly assigned to two groups and treated with either osimertinib with che… (full text at CIViC) PMID 37937763 · Planchard et al., 2023 · Open in CIViC | civic |
| EGFR T790M AND EGFR Exon 19 Deletion | Osimertinib | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID11598This phase 3 trial (NCT02151981) involved 419 patients with EGFR T790M mutant NSCLC who progressed after first-line EGFR inhibitor therapy (gefitinib, erlotinib, or afatinib) and were either treated w… (full text at CIViC) PMID 27959700 · Mok et al., 2017 · Open in CIViC | civic |